AI Engines For more Details: Perplexity Kagi Labs You
Menopausal Symptom Relief: Estradiol valerate is commonly prescribed to alleviate symptoms associated with menopause, such as hot flashes, night sweats, vaginal dryness, mood swings, and sleep disturbances. By replenishing estrogen levels in the body, estradiol valerate can help reduce the severity and frequency of these symptoms, improving overall quality of life for menopausal women.
Prevention of Osteoporosis: Estrogen, including estradiol valerate, plays a crucial role in maintaining bone density and strength. Hormone replacement therapy with estradiol valerate may help prevent or slow down the progression of osteoporosis, a condition characterized by weakened and brittle bones that are more prone to fractures. It is especially beneficial for postmenopausal women who are at an increased risk of developing osteoporosis due to estrogen deficiency.
Vaginal Atrophy and Dryness: Estradiol valerate therapy, particularly in vaginal formulations such as creams, tablets, or rings, is used to treat vaginal atrophy and dryness in menopausal women. By replenishing estrogen levels in the vaginal tissues, estradiol valerate can restore moisture, elasticity, and thickness to the vaginal lining, reducing symptoms such as itching, burning, and discomfort during intercourse.
Hypoestrogenism: Estradiol valerate may be prescribed to individuals with conditions characterized by low estrogen levels, such as primary ovarian insufficiency (premature ovarian failure), hypogonadism, or certain surgical menopause situations (e.g., oophorectomy). Supplemental estradiol valerate helps maintain estrogen levels within the normal physiological range, supporting overall health and well-being.
Gender-Affirming Hormone Therapy: In transgender women (individuals assigned male at birth but who identify and live as female), estradiol valerate is used as part of gender-affirming hormone therapy to induce feminization of secondary sexual characteristics, such as breast development, redistribution of body fat, and reduction of facial/body hair growth. It is often administered in combination with anti-androgens to suppress testosterone levels.
Endometrial Cancer Risk: Unopposed estrogen therapy, meaning estrogen without a progestin component, can increase the risk of endometrial hyperplasia (overgrowth of the uterine lining) and endometrial cancer in women who have not undergone a hysterectomy. Therefore, estrogen therapy is often combined with a progestin in women with an intact uterus to prevent endometrial hyperplasia and reduce the risk of endometrial cancer.
Breast Cancer Risk: The use of estrogen therapy, including estradiol valerate-containing formulations, has been associated with an increased risk of breast cancer, particularly with long-term use and in women with certain risk factors. The decision to initiate estrogen therapy should be individualized based on a thorough assessment of each patient's medical history, risk factors, and treatment goals, weighing the potential benefits against the risks.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Increases |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.8 | 0.3 | 15 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 4.2 | 2.3 | 0.83 |
| Allergies | 6.5 | 3.9 | 0.67 |
| Allergy to milk products | 1.7 | 2.7 | -0.59 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.1 | 8.5 | -0.39 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 1.8 | 1.06 |
| Ankylosing spondylitis | 4.1 | 2.1 | 0.95 |
| Anorexia Nervosa | 2.3 | 3.1 | -0.35 |
| Antiphospholipid syndrome (APS) | 1.9 | 0.3 | 5.33 |
| Asthma | 6.6 | 2.2 | 2 |
| Atherosclerosis | 3.5 | 1.7 | 1.06 |
| Atrial fibrillation | 4.2 | 3.1 | 0.35 |
| Autism | 10.7 | 10.7 | 0 |
| Autoimmune Disease | 1.8 | 1 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.4 | -0.33 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.3 | 2.3 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 1 | 1.5 | -0.5 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 1.4 | 3.5 | -1.5 |
| Carcinoma | 5.1 | 2.6 | 0.96 |
| Celiac Disease | 3.7 | 3.7 | 0 |
| Cerebral Palsy | 1.2 | 1.9 | -0.58 |
| Chronic Fatigue Syndrome | 4.5 | 7.3 | -0.62 |
| Chronic Kidney Disease | 5.2 | 2.6 | 1 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.9 | 1.6 | 0.81 |
| Chronic Urticaria (Hives) | 2.2 | 1.2 | 0.83 |
| Coagulation / Micro clot triggering bacteria | 2.3 | 1.9 | 0.21 |
| Cognitive Function | 2.6 | 2 | 0.3 |
| Colorectal Cancer | 7 | 3.7 | 0.89 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 3.1 | 2.7 | 0.15 |
| COVID-19 | 9.9 | 12.2 | -0.23 |
| Crohn's Disease | 10.4 | 5.9 | 0.76 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.9 | 1.9 | -1.11 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.9 | 2.7 | -0.42 |
| Denture Wearers Oral Shifts | 1.7 | 1.7 | |
| Depression | 13.3 | 9.5 | 0.4 |
| Dermatomyositis | 0.4 | 0.3 | 0.33 |
| Eczema | 2.1 | 2.8 | -0.33 |
| Endometriosis | 3.6 | 1.7 | 1.12 |
| Eosinophilic Esophagitis | 0.3 | 0.7 | -1.33 |
| Epilepsy | 5 | 2.3 | 1.17 |
| erectile dysfunction | 1.4 | 0.4 | 2.5 |
| Fibromyalgia | 2.8 | 2.6 | 0.08 |
| Functional constipation / chronic idiopathic constipation | 5.9 | 4.9 | 0.2 |
| gallstone disease (gsd) | 4.3 | 1.1 | 2.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.7 | 1.29 |
| Generalized anxiety disorder | 3.5 | 2.7 | 0.3 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.4 | -0.4 | |
| Gout | 2.8 | 1.1 | 1.55 |
| Graves' disease | 1.6 | 3.1 | -0.94 |
| Gulf War Syndrome | 2.2 | 1.4 | 0.57 |
| Halitosis | 2 | 0.4 | 4 |
| Hashimoto's thyroiditis | 4.2 | 2.1 | 1 |
| Heart Failure | 4.8 | 1.9 | 1.53 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.6 | 1.6 | |
| High Histamine/low DAO | 1.7 | 0.6 | 1.83 |
| hypercholesterolemia (High Cholesterol) | 1.4 | 1.4 | |
| hyperglycemia | 2.7 | 1.7 | 0.59 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.9 | 0.56 |
| hypersomnia | 0.8 | -0.8 | |
| hypertension (High Blood Pressure | 5.2 | 6.6 | -0.27 |
| Hypothyroidism | 1.3 | -1.3 | |
| Hypoxia | 3.3 | 0.9 | 2.67 |
| IgA nephropathy (IgAN) | 2.5 | 3.4 | -0.36 |
| Inflammatory Bowel Disease | 8.9 | 10.1 | -0.13 |
| Insomnia | 3.5 | 2 | 0.75 |
| Intelligence | 1.7 | 0.6 | 1.83 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 8 | 5.5 | 0.45 |
| ischemic stroke | 2.8 | 1.8 | 0.56 |
| Liver Cirrhosis | 8.9 | 4.5 | 0.98 |
| Long COVID | 7.7 | 7.7 | 0 |
| Low bone mineral density | 0.1 | 0.8 | -7 |
| Lung Cancer | 2.1 | 1 | 1.1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.7 | 0.9 | 0.89 |
| ME/CFS with IBS | 1 | 2.1 | -1.1 |
| ME/CFS without IBS | 1.2 | 2.4 | -1 |
| membranous nephropathy | 0.4 | 0.4 | |
| Menopause | 2.3 | 0.5 | 3.6 |
| Metabolic Syndrome | 9.6 | 8.5 | 0.13 |
| Mood Disorders | 11.9 | 8.9 | 0.34 |
| multiple chemical sensitivity [MCS] | 1 | 0.7 | 0.43 |
| Multiple Sclerosis | 6 | 7.7 | -0.28 |
| Multiple system atrophy (MSA) | 1.9 | -1.9 | |
| myasthenia gravis | 1 | 0.7 | 0.43 |
| neuropathic pain | 0.6 | 2 | -2.33 |
| Neuropathy (all types) | 0.6 | 2.5 | -3.17 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 7.3 | 4.6 | 0.59 |
| NonCeliac Gluten Sensitivity | 1 | 1.2 | -0.2 |
| Obesity | 11.1 | 10.2 | 0.09 |
| obsessive-compulsive disorder | 5.9 | 4.4 | 0.34 |
| Osteoarthritis | 3.5 | 1.3 | 1.69 |
| Osteoporosis | 2.5 | 1.4 | 0.79 |
| pancreatic cancer | 1.4 | 0.4 | 2.5 |
| Parkinson's Disease | 8.9 | 8.9 | 0 |
| Polycystic ovary syndrome | 9.2 | 3.4 | 1.71 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1 | 1.8 | -0.8 |
| Primary sclerosing cholangitis | 1.7 | 2.9 | -0.71 |
| Psoriasis | 3.5 | 4 | -0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.8 | 5.6 | 0.57 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 6.6 | 3.1 | 1.13 |
| scoliosis | 0.6 | 0.6 | 0 |
| Sjögren syndrome | 2.5 | 3.3 | -0.32 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.6 | 2 |
| Stress / posttraumatic stress disorder | 3.8 | 2.7 | 0.41 |
| Systemic Lupus Erythematosus | 4.5 | 1.6 | 1.81 |
| Tic Disorder | 1.6 | 1.8 | -0.13 |
| Tourette syndrome | 1 | 0.9 | 0.11 |
| Type 1 Diabetes | 3.7 | 4.9 | -0.32 |
| Type 2 Diabetes | 10.3 | 8.1 | 0.27 |
| Ulcerative colitis | 7.3 | 6.5 | 0.12 |
| Unhealthy Ageing | 6.3 | 2.4 | 1.63 |
| Vitiligo | 2.9 | 1.5 | 0.93 |
